To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC46580 | SNIPER(TACC3)-2 |
SNIPER(TACC3)-2 targets the TACC3 protein for degradation via the ubiquitin-proteasome pathway. SNIPER(TACC3)-2 induces cancer cell death.
More description
|
|
| DC46579 | SNIPER(TACC3)-1 |
SNIPER(TACC3)-1 targets the TACC3 protein for degradation via the ubiquitin-proteasome pathway. SNIPER(TACC3)-1 induces cancer cell death.
More description
|
|
| DC46578 | SNIPER(ABL)-049 |
SNIPER(ABL)-049, conjugating Imatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 100 μM.
More description
|
|
| DC46577 | SNIPER(ABL)-044 |
SNIPER(ABL)-044, conjugating HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 μM.
More description
|
|
| DC46576 | SNIPER(ABL)-019 |
SNIPER(ABL)-019, conjugating Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 0.3 μM.
More description
|
|
| DC46575 | PROTAC ER Degrader-2 |
PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
More description
|
|
| DC46573 | BzNH-BS |
BzNH-BS contains two different ligands, methyl-bestatin (MeBS) for cIAP1 and benzoyl-amide, which are connected by linkers. MeBS as a ligand for cellular inhibitor of apoptosis protein 1 (cIAP1) ubiquitin ligase.
More description
|
|
| DC46475 | PROTAC Bcl-xL degrader-1 |
PROTAC Bcl-xL degrader-1 is a PROTAC that comprises a Bcl-xL ligand binding group, a linker and an IAP E3 ligases binding group. PROTAC Bcl-xL degrader-1 is a potent Bcl-xL degrader, and shows toxicity for human platelets and MyLa 1929 cells with IC50 values of 62 nM and 8.5 μM, respectively.
More description
|
|
| DC46448 | Mal-PEG2-NH2 TFA |
Mal-PEG2-NH2 (TFA) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|
| DC46308 | Ipatasertib-NH2 dihydrochloride |
Ipatasertib-NH2 dihydrochloride is a ligand for target protein AKT for PROTAC (INY-03-041). INY-03-041 is composed of Ipatasertib-NH2, a ten-hydrocarbon linker, and a CRBN ligand Lenalidomide for E3 ubiquitin ligase.
More description
|
|
| DC46179 | PROTAC Bcl-xL ligand-1 |
PROTAC Bcl-xL ligand-1 is a ligand for Bcl-xL that can be used in the synthesis of PROTACs.
More description
|
|
| DC46178 | PROTAC KRAS G12C degrader-1 |
PROTAC KRAS G12C degrader-1 is a PROTAC-based KRASG12C degrader, with an IC50 of 414 nM for CRBN. PROTAC KRAS G12C degrader-1 induces CRBN/ KRASG12C dimerization and degrades GFP- KRASG12C in reporter cells.
More description
|
|
| DC45856 | PROTAC IRAK4 degrader-6 |
PROTAC IRAK4 degrader-6 is a PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-172.
More description
|
|
| DC45855 | PROTAC IRAK4 degrader-4 |
PROTAC IRAK4 degrader-4 is a PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-127.
More description
|
|
| DC45853 | PROTAC BRD4 Degrader-15 |
PROTAC BRD4 Degrader-15 is a potent BRD4 degrader, with IC50s of 7.2 nM and 8.1 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-15 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells.
More description
|
|
| DC45756 | 5-Boc-amino-pentanoic acid |
5-Boc-amino-pentanoic acid (Boc-5-aminovaleric acid, Boc-NH-C4-acid, Boc-5-Ava-OH) is a PROTAC linker that belongs to a Alkyl/ether linker. Boc-NH-C4-acid is applicable to the synthesis of PROTAC1, and specifically degrades EED, EZH2, and SUZ12 in the PRC2 Complex.
More description
|
|
| DC45755 | Bis-PEG12-endo-BCN |
Bis-PEG12-endo-BCN is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|
| DC45258 | Benzyl-PEG12-Ots |
Benzyl-PEG12-Ots is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
More description
|
|
| DC45257 | Benzyl-PEG10-Ots |
Benzyl-PEG10-Ots is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
More description
|
|
| DC45256 | Azido-PEG10-propargyl |
Azido-PEG10-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|
| DC45255 | Bis-sulfone-PEG4-Tetrazine |
Bis-sulfone-PEG4-Tetrazine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|
| DC45254 | Fmoc-PEG10-NHS ester |
Fmoc-PEG10-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|
| DC45253 | Fmoc-PEG9-NHS ester |
Fmoc-PEG9-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|
| DC45252 | m-PEG14-NHS ester |
m-PEG14-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|
| DC45251 | Propargyl-PEG13-Boc |
Propargyl-PEG13-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|
| DC45250 | Mal-PEG10-NHS ester |
Mal-PEG10-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|
| DC45249 | Mal-PEG10-Boc |
Mal-PEG10-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|
| DC45248 | Mal-amido-PEG7-NHS ester |
Mal-amido-PEG7-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|
| DC45247 | Propargyl-PEG13-OH |
Propargyl-PEG13-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|
| DC45246 | Propargyl-PEG12-acid |
Propargyl-PEG12-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|